Highlights Merck & Co., Inc.

Stocks

MRK

US58933Y1055

Pharmaceuticals

Market Closed - NYSE Other stock markets 01:32:41 10/06/2026 am IST			After hours 05:30:00 am
119.60 ^USD	+0.07%		119.24	-0.30%

09/06	Merck & Co., Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 11:20 AM
09/06	What Bundibugyo Ebola vaccines and treatments are under development	RE

Highlights

09/06	Cancer vaccines based on mRNA advance, despite US cuts	RE
09/06	Gilead Sciences, Inc. And Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, An Oral Once-Weekly HIV Treatment	CI
09/06	Merck and Gilead Sciences, Inc. Provides Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study	CI
04/06	Merck to Pay Over $50 Million to Settle More Than 200 Gardasil Cases	MT
04/06	Merck to Pay Over $50 Million to Settle More Than 200 Gardasil Cases, Bloomberg Reports	MT
03/06	Agilent Gets US FDA Clearance for Expanded Use of Cancer Test on Dako Omnis Platform	MT
29/05	Merck & Co., Inc. Grants Breakthrough Therapy Designation For Calderasib MK-1084 For First-Line Treatment Of Advanced Or Metastatic Non-Small Cell Lung Cancer With KRAS G12C-Mutation	CI
27/05	Merck Co Inc declares Q3 2026 dividend of $0.85 per share	RE
26/05	Merck Keeps Quarterly Dividend at $0.85 a Share, Payable July 8 to Holders of Record June 15	MT
26/05	Merck & Co., Inc. Declares Quarterly Dividend for the Third Quarter of 2026, Payable on July 8, 2026	CI
26/05	Adcendo ApS and MSD Enter Clinical Collaboration and Supply Agreement to Evaluate ADCE-T02 in Combination with KEYTRUDA (Pembrolizumab) in Phase Ib Study in Patients with Advanced Solid Tumors	CI
22/05	Merck's Keytruda, Padcev Combination to Treat Bladder Cancer Receives Positive EU Recommendation; Shares Up Pre-Bell	MT
22/05	Merck & Co., Inc. Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer	CI
22/05	EMA's CHMP recommends extension to marketing authorisation for Wegovy	RE
22/05	Moderna, Merck cancer combo cuts melanoma spread risk at five years	RE
19/05	Exelixis, Inc. Announces Clinical Development Collaboration with Merck for Phase 3 Stellar-316 Pivotal Trial for Patients with Colorectal Cancer	CI
18/05	Merck's drug helps uterine cancer patients live longer in late-stage trial	RE
18/05	Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan Meets Primary Endpoints in Advanced or Recurrent Endometrial Cancer	CI
18/05	Regeneron drops after skin cancer treatment misses late-stage trial goal	RE
12/05	Merck Highlights New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research At Asco 2026	CI
05/05	Merck Completes Terns Pharmaceuticals Acquisition	MT
30/04	Merck beats quarterly sales expectations as Keytruda fuels growth	RE
30/04	Merck Q1 adjusted loss per share $1.28 versus IBES estimate $-1.51	RE
30/04	Merck posts quarterly loss due to Cidara charge, sales rise 5%	RE
30/04	Merck 1Q Sales Rise on Continued Keytruda Growth -- Update	DJ